首页 > 最新文献

Australian Prescriber最新文献

英文 中文
Asciminib for chronic myeloid leukaemia. 阿西米尼治疗慢性髓性白血病。
IF 2.7 Q2 PHARMACOLOGY & PHARMACY
Australian Prescriber
Pub Date : 2022-12-01 DOI: 10.18773/austprescr.2022.070
{"title":"Asciminib for chronic myeloid leukaemia.","authors":"","doi":"10.18773/austprescr.2022.070","DOIUrl":"https://doi.org/10.18773/austprescr.2022.070","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"45 6","pages":"211-212"},"PeriodicalIF":2.7,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/0d/38/austprescr-45-211.PMC9722350.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10740660","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Coronary artery disease in women. 女性冠状动脉疾病
IF 2.7 Q2 PHARMACOLOGY & PHARMACY
Australian Prescriber
Pub Date : 2022-12-01 Epub Date: 2022-11-30 DOI: 10.18773/austprescr.2022.065
Natalie Montarello, Wai Ping Alicia Chan

Cardiovascular disease is the leading global cause of death in women but remains underdiagnosed and undertreated. Health professionals play an important role in improving the heart health of Australian women. Routine heart health checks should be offered to all women 45 years of age and older and to all Aboriginal and Torres Strait Islander women 30 years of age and older. Cardiovascular risk assessment in women must include traditional and sex-specific risk factors, including their pregnancy history and early-onset menopause. Women with pregnancy-related hypertensive and metabolic disorders have an increased long-term cardiovascular risk and require close monitoring. Women with acute coronary syndrome may not experience classical chest pain. More often, they experience cardiovascular events in the absence of obstructive coronary disease and have poorer cardiovascular outcomes. The recognition of sex-specific differences and more sex-specific trials are key to improving clinical outcomes.

心血管疾病是全球妇女死亡的主要原因，但仍未得到充分诊断和治疗。保健专业人员在改善澳大利亚妇女的心脏健康方面发挥着重要作用。应向所有45岁及以上的妇女和所有30岁及以上的土著和托雷斯海峡岛民妇女提供例行心脏健康检查。女性心血管风险评估必须包括传统的和性别特异性的风险因素，包括她们的怀孕史和早发性更年期。患有妊娠相关高血压和代谢性疾病的妇女有增加的长期心血管风险，需要密切监测。患有急性冠状动脉综合征的女性可能不会经历典型的胸痛。更常见的是，他们在没有阻塞性冠状动脉疾病的情况下经历心血管事件，心血管预后较差。认识到性别特异性差异和更多的性别特异性试验是改善临床结果的关键。
{"title":"Coronary artery disease in women.","authors":"Natalie Montarello, Wai Ping Alicia Chan","doi":"10.18773/austprescr.2022.065","DOIUrl":"10.18773/austprescr.2022.065","url":null,"abstract":"<p><p>Cardiovascular disease is the leading global cause of death in women but remains underdiagnosed and undertreated. Health professionals play an important role in improving the heart health of Australian women. Routine heart health checks should be offered to all women 45 years of age and older and to all Aboriginal and Torres Strait Islander women 30 years of age and older. Cardiovascular risk assessment in women must include traditional and sex-specific risk factors, including their pregnancy history and early-onset menopause. Women with pregnancy-related hypertensive and metabolic disorders have an increased long-term cardiovascular risk and require close monitoring. Women with acute coronary syndrome may not experience classical chest pain. More often, they experience cardiovascular events in the absence of obstructive coronary disease and have poorer cardiovascular outcomes. The recognition of sex-specific differences and more sex-specific trials are key to improving clinical outcomes.</p>","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"45 6","pages":"193-199"},"PeriodicalIF":2.7,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/25/5c/austprescr-45-193.PMC9722351.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10740667","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Bariatric surgery and medicines: from first principles to practice. 减肥手术和药物:从最初的原理到实践。
IF 2.7 Q2 PHARMACOLOGY & PHARMACY
Australian Prescriber
Pub Date : 2022-10-01 DOI: 10.18773/austprescr.2022.053
Teresa Girolamo, Rosemary Allin

Obesity is a major public health issue with significant health and financial costs. Almost one in three Australian adults are living with obesity Bariatric surgery can have a role in the management of obesity. There is evidence for its effectiveness in preventing or reversing chronic health conditions The type of bariatric surgery can significantly impact the absorption, distribution, metabolism or elimination of orally administered drugs. Some changes can be predicted from pharmacokinetic and physiological effects, but management should be individualised The effect of weight loss itself after bariatric surgery may require drug doses to be altered A review of the patient's medicines and ongoing follow-up are important before and after surgery to ensure optimal outcomes.

肥胖是一个重大的公共卫生问题，具有巨大的健康和经济成本。几乎三分之一的澳大利亚成年人患有肥胖症，减肥手术在控制肥胖方面可以发挥作用。有证据表明它在预防或逆转慢性健康状况方面的有效性。减肥手术的类型可以显著影响口服给药药物的吸收、分布、代谢或消除。一些变化可以从药代动力学和生理效应中预测出来，但治疗应个体化。减肥手术后体重减轻本身的效果可能需要改变药物剂量。术前和术后对患者药物的回顾和持续的随访是重要的，以确保最佳结果。
{"title":"Bariatric surgery and medicines: from first principles to practice.","authors":"Teresa Girolamo,&nbsp;Rosemary Allin","doi":"10.18773/austprescr.2022.053","DOIUrl":"https://doi.org/10.18773/austprescr.2022.053","url":null,"abstract":"<p><p>Obesity is a major public health issue with significant health and financial costs. Almost one in three Australian adults are living with obesity Bariatric surgery can have a role in the management of obesity. There is evidence for its effectiveness in preventing or reversing chronic health conditions The type of bariatric surgery can significantly impact the absorption, distribution, metabolism or elimination of orally administered drugs. Some changes can be predicted from pharmacokinetic and physiological effects, but management should be individualised The effect of weight loss itself after bariatric surgery may require drug doses to be altered A review of the patient's medicines and ongoing follow-up are important before and after surgery to ensure optimal outcomes.</p>","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"45 5","pages":"162-166"},"PeriodicalIF":2.7,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/3b/76/austprescr-45-162.PMC9584784.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10429472","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Drospirenone and mood. 屈螺酮与情绪
IF 3.4 Q2 PHARMACOLOGY & PHARMACY
Australian Prescriber
Pub Date : 2022-08-01 DOI: 10.18773/austprescr.2022.048
Andrew Zuschmann
{"title":"Drospirenone and mood.","authors":"Andrew Zuschmann","doi":"10.18773/austprescr.2022.048","DOIUrl":"10.18773/austprescr.2022.048","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"45 4","pages":"116"},"PeriodicalIF":3.4,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/32/09/austprescr-45-116.PMC9427626.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40360597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
How to step down asthma preventer treatment in patients with well-controlled asthma - more is not always better. 如何在控制良好的哮喘患者中减少哮喘预防药物的治疗-越多并不总是越好。
IF 2.7 Q2 PHARMACOLOGY & PHARMACY
Australian Prescriber
Pub Date : 2022-08-01 DOI: 10.18773/austprescr.2022.033
Helen K Reddel, Gloria J Foxley, Sharon R Davis

Most of the benefit of asthma preventer inhalers is seen with low doses. However, many Australian patients are prescribed doses of inhaled corticosteroids that are higher than necessary to control their asthma. Prescribing unnecessarily high preventer doses increases the patient's risk of adverse effects. They may also increase the patient's out-of-pocket costs. Asthma guidelines recommend considering a step-down in preventer treatment after asthma has been well controlled for two to three months in adults and for six months in children. The step-down process should be individualised for each patient. Preventive therapy should not be stopped completely.

预防哮喘吸入器的大多数益处是在低剂量时看到的。然而，许多澳大利亚患者吸入的皮质类固醇剂量高于控制哮喘所需的剂量。开出不必要的高剂量预防剂会增加患者产生不良反应的风险。它们也可能增加病人的自付费用。哮喘指南建议在成人哮喘控制好2 - 3个月，儿童哮喘控制好6个月后，考虑逐步减少预防剂治疗。降压过程应针对每位患者个体化。预防治疗不应完全停止。
{"title":"How to step down asthma preventer treatment in patients with well-controlled asthma - more is not always better.","authors":"Helen K Reddel,&nbsp;Gloria J Foxley,&nbsp;Sharon R Davis","doi":"10.18773/austprescr.2022.033","DOIUrl":"https://doi.org/10.18773/austprescr.2022.033","url":null,"abstract":"<p><p>Most of the benefit of asthma preventer inhalers is seen with low doses. However, many Australian patients are prescribed doses of inhaled corticosteroids that are higher than necessary to control their asthma. Prescribing unnecessarily high preventer doses increases the patient's risk of adverse effects. They may also increase the patient's out-of-pocket costs. Asthma guidelines recommend considering a step-down in preventer treatment after asthma has been well controlled for two to three months in adults and for six months in children. The step-down process should be individualised for each patient. Preventive therapy should not be stopped completely.</p>","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"45 4","pages":"125-129"},"PeriodicalIF":2.7,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/04/f8/austprescr-45-125.PMC9427634.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40361740","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Onasemnogene abeparvovec for spinal muscular atrophy. Onasemnogene abeparvovec 用于脊髓性肌萎缩症。
IF 3.4 Q2 PHARMACOLOGY & PHARMACY
Australian Prescriber
Pub Date : 2022-08-01 Epub Date: 2022-07-07 DOI: 10.18773/austprescr.2022.044
{"title":"Onasemnogene abeparvovec for spinal muscular atrophy.","authors":"","doi":"10.18773/austprescr.2022.044","DOIUrl":"10.18773/austprescr.2022.044","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"45 4","pages":"140-141"},"PeriodicalIF":3.4,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/aa/6b/austprescr-45-140.PMC9427620.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40360599","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cabotegravir. Cabotegravir。
IF 2.7 Q2 PHARMACOLOGY & PHARMACY
Australian Prescriber
Pub Date : 2022-08-01 Epub Date: 2022-07-07 DOI: 10.18773/austprescr.2022.039
{"title":"Cabotegravir.","authors":"","doi":"10.18773/austprescr.2022.039","DOIUrl":"https://doi.org/10.18773/austprescr.2022.039","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"45 4","pages":"134-135"},"PeriodicalIF":2.7,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/67/71/austprescr-45-134.PMC9427628.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40360602","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Multimodal interventions for pain management. 疼痛管理的多模式干预。
IF 2.7 Q2 PHARMACOLOGY & PHARMACY
Australian Prescriber
Pub Date : 2022-08-01 DOI: 10.18773/austprescr.2022.045
{"title":"Multimodal interventions for pain management.","authors":"","doi":"10.18773/austprescr.2022.045","DOIUrl":"https://doi.org/10.18773/austprescr.2022.045","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"45 4","pages":"113"},"PeriodicalIF":2.7,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f2/18/austprescr-45-113.PMC9427633.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40361739","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Risdiplam for spinal muscular atrophy. 里斯地普兰治疗脊髓性肌萎缩症。
IF 2.7 Q2 PHARMACOLOGY & PHARMACY
Australian Prescriber
Pub Date : 2022-08-01 Epub Date: 2022-07-07 DOI: 10.18773/austprescr.2022.041
The most common form of spinal muscular atrophy is due to mutations in a gene located on chromosome 5. This is sometimes referred to as 5q SMA. As a result of the mutation there is reduced production of survival motor neuron (SMN) protein. This leads to progressive muscle weakness. The most frequent type of spinal muscular atrophy (SMA1) presents in babies as hypotonia, poor head control and impaired swallowing. Due to neuromuscular weakness, respiratory support will be needed and life expectancy is usually under two years.
{"title":"Risdiplam for spinal muscular atrophy.","authors":"","doi":"10.18773/austprescr.2022.041","DOIUrl":"https://doi.org/10.18773/austprescr.2022.041","url":null,"abstract":"The most common form of spinal muscular atrophy is due to mutations in a gene located on chromosome 5. This is sometimes referred to as 5q SMA. As a result of the mutation there is reduced production of survival motor neuron (SMN) protein. This leads to progressive muscle weakness. The most frequent type of spinal muscular atrophy (SMA1) presents in babies as hypotonia, poor head control and impaired swallowing. Due to neuromuscular weakness, respiratory support will be needed and life expectancy is usually under two years.","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"45 4","pages":"142-143"},"PeriodicalIF":2.7,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/39/22/austprescr-45-142.PMC9427635.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40360596","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Progesterone and progestogens. 黄体酮和孕激素。
IF 2.7 Q2 PHARMACOLOGY & PHARMACY
Australian Prescriber
Pub Date : 2022-08-01 DOI: 10.18773/austprescr.2022.047
Joanne Lipinski
I am concerned by the ambiguity about progesterone/progestogen in the article ‘Hormonal contraception and mood disorders’.1 The summary correctly states ‘The link between oral contraceptive pills and depression relates to the amount and type of progestogen contained in these pills’, but the article subsequently says that progesterone can worsen mood symptoms. Plausible links are said to include progesterone augmentation of GABA-induced inhibition of glutamate transmission, and progesterone increasing the concentrations of monoamine oxidase, resulting in decreased serotonin concentrations. However, these links should be referring to progestogen rather than progesterone.
{"title":"Progesterone and progestogens.","authors":"Joanne Lipinski","doi":"10.18773/austprescr.2022.047","DOIUrl":"https://doi.org/10.18773/austprescr.2022.047","url":null,"abstract":"I am concerned by the ambiguity about progesterone/progestogen in the article ‘Hormonal contraception and mood disorders’.1 The summary correctly states ‘The link between oral contraceptive pills and depression relates to the amount and type of progestogen contained in these pills’, but the article subsequently says that progesterone can worsen mood symptoms. Plausible links are said to include progesterone augmentation of GABA-induced inhibition of glutamate transmission, and progesterone increasing the concentrations of monoamine oxidase, resulting in decreased serotonin concentrations. However, these links should be referring to progestogen rather than progesterone.","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"45 4","pages":"115"},"PeriodicalIF":2.7,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/5e/eb/austprescr-45-115.PMC9427621.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40360600","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
类型
全部 化学•材料 生命科学 医学 物理 工程技术 环境•农林 材料科学 地球科学 法学 管理学 化学 环境科学与生态学 计算机科学 教育学 经济学 农林科学 人文科学 生物学 数学 物理与天体物理 心理学 综合性期刊 其他 工业工程 理学 历史学 农学 文学 信息工程
数据库
全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley
期刊
Australian Prescriber
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
﹀
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们：info@booksci.cn
Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1